サンプル依頼リスト カート
  • English
  • Korean
表紙：腸管管理システムの世界市場-2023年～2030年
市場調査レポート
商品コード
1374807

腸管管理システムの世界市場-2023年～2030年

Global Bowel Management Systems Market -2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
腸管管理システムの世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

腸管管理システム（BMS）は一時的な封じ込め器具であり、液状便または半液状便のある、腸管管理がほとんどできない、またはできない寝たきり患者や失禁患者に適応されます。また、重度の熱傷を負った患者の腸機能管理、性器、会陰または肛門の皮膚移植の治癒促進、形成手術後の感染管理にも適応されます。

便失禁管理のための腸管管理システムは、他のすべての便失禁管理の選択肢を検討した後にのみ挿入すべきです。腸管管理システムの使用は、患者のケアを担当する医療チームとの間で、以下を考慮した総合的な評価後に合意されなければならないです。

感染管理、器具に関連した皮膚破壊のリスク、プライバシーと尊厳、および使用禁忌を考慮した患者の総合的な評価に基づき、患者のケアを担当する医療チームと合意しなければならないです。

腸管管理システムは、感染の拡大防止に加え、鼠径部に留置された尿道カテーテル、静脈カテーテル、動脈カテーテルへの糞便細菌汚染を防止し、局所感染や全身感染を引き起こす可能性があります。

市場力学：促進要因と抑制要因

技術的進歩と製品発売の増加

主要企業による腸管管理システムの進歩や新規製品の発売の増加は、予測期間中の市場成長をさらに促進します。

例えば、2023年4月、NHS財団トラストが所有するデジタルヘルス企業health callは、膀胱と腸の問題のための自己紹介プラットフォームを立ち上げ、ユーザーはGPを受診せずにトラストのウェブサイトからサービスを自己紹介できるようになっています。このプラットフォームは、ヘルプやサポートを求めるプロセスを簡素化し、ユーザーが正確で事実に基づいた紹介をすることを可能にし、トラストによるトリアージが容易になります。

2023年に開始されたこのプラットフォームは、トリアージを大幅に改善し、紹介を迅速化しました。このソリューションはまた、紹介の明確な監査証跡を提供し、プロセスをスピードアップします。テクノロジーが膀胱と腸のケアに果たす役割は大きくなっており、9つのNHSトラストがAI機器を導入し、英国の新興企業Motilentは国立医療介護研究機構から資金援助を受けています。

さらに、2022年2月には、世界有数のストーマケア製品メーカーであるコロプラストが、最新の製品イノベーションである「SenSura Mio」を今年シンガポールで発売しました。シンガポールは、オストメイト、すなわちオストメイトを経験し、現在ストーマと共に生活している人々の生活の質を向上させることを目的としたSenSura Mioを発売した東南アジア初の国です。

さらに、炎症性腸疾患の有病率の上昇、高齢者人口の増加、様々な腸管管理製品の発売、最近および新たな可能性のある承認、好意的な償還政策は、予測期間中の市場成長をさらに促進するでしょう。

市場力学：市場抑制要因

便失禁の非侵襲的臨床管理に対する患者の嗜好。現在、便失禁は侵襲的（外科的）または非侵襲的に管理することができます。外科的治療の標準的な方法には、肛門管への生体材料の注入、肛門管の高周波治療、肛門筋損傷の外科的修復、仙骨神経刺激、人工腸括約筋、肛門括約筋を補強する筋移植、ストーマの造設などがあります。これらはしばしば長期にわたる患者のリハビリを必要とし、また非常に不便で、ひどい痛みを伴うことさえあります。

また、認知度の低さ、規制上の懸念、懸念される副作用なども、予測期間中の市場成長率を妨げる要因となっています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 技術の進歩
      • 主要プレーヤーによる製品発売の増加
    • 抑制要因
      • 長期にわたる患者のリハビリテーション
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMI意見

第6章 COVID-19分析

第7章 製品タイプ別

  • 人工肛門バッグ
  • 灌流システム
  • 神経調節装置
  • その他

第8章 患者タイプ別

  • 成人
  • 小児

第9章 用途別

  • 脊髄損傷
  • 神経疾患
  • 多発性硬化症
  • 脳卒中

第10章 エンドユーザー別

  • 病院
  • 外来手術センター（ASC）
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Becton, Dickinson and Company
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Coloplast Pty Ltd.
  • ConvaTec Group plc.
  • B Braun SE.
  • Consure Medical Pvt. Ltd.
  • GBUK Group Ltd.
  • Wellandmedical
  • Wellspect
  • ProSys International Ltd
  • Qufora

第14章 付録

目次
Product Code: MD7246

Overview

Bowel management systems (BMS) are temporary containment devices, indicated for bedridden or immobilised incontinent patients, with little or no bowel control, who have a liquid or semi-liquid stool. They are also indicated for patients with severe burns to manage their bowel function, promote healing of genital, perineal or anal skin grafts and maintain infection control following plastic surgery.

A bowel management system for the control of faecal incontinence should only be inserted once all other faecal incontinence management alternatives have been considered. The use of a bowel management system must be agreed upon with the medical team in charge of the patient's care following a holistic assessment of

the patient which has taken into consideration: infection control, risk of device-related skin breakdown, privacy and dignity, and contraindications for use.

In addition to preventing the spread of infection, a bowel management system can potentially prevent faecal bacterial contamination of urinary, intravenous and arterial catheters located in the groin area, causing local and systemic infection.

Market Dynamics: Drivers and Restraints

Rise in the technological advancements and product launches

The rise in the advancements in bowel management systems and novel product launches by key players will further drive the market growth during the forecast period.

For instance, in April 2023, NHS foundation trust owned digital health company health call launched a self-referral platform for bladder and bowel issues, allowing users to self-refer to services from the trust website without seeing their GP. The platform simplifies the process of seeking help and support, allowing users to give precise, factual referrals that are easier to triage by the trust.

The platform launched in 2023, has significantly improved triage and sped up referrals, allowing patients to access the service 24/7. Th,e solution also provides a clear audit trail for referrals and speeds up the process. Technology is playing a growing role in bladder and bowel care, with AI devices being trailed by nine NHS trusts and UK start-up Motilent receiving funding from the National Institute for Health and Care Research.

Moreover, in February 2022, Coloplast, one of the world's leading manufacturers of stoma care products launched its latest product innovation, the SenSura Mio in Singapore this year. Singapore is the first country in Southeast Asia that launch SenSura Mio which aims to improve the quality of life of ostomates, or people who have gone through ostomy and are now living with stoma.

Furthermore, the rise in the prevalence of inflammatory bowel diseases, the increasing geriatric population, the launch of various bowel management products, recent and new potential approvals, and Favorable reimbursement policies, will further drive the market growth during the forecast period.

Market Dynamics: Restraint

Patient preference for non-invasive clinical management of Fecal incontinence. Currently, Fecal incontinence can be managed invasively (surgically) or non-invasively. Standard modes of surgical treatment include the injection of biomaterials into the anal canal, radiofrequency treatment of the anal canal, surgical repair of anal muscle injuries, sacral nerve stimulation, artificial bowel sphincter, muscle transposition to reinforce the anal sphincter and the creation of a stoma. These often require long-term patient rehabilitation and also it is highly inconvenient and even severely painful.

Also, lack of awareness, regulatory concerns, and concerned side effects are also the factors that hamper the market growth rate during the forecast period.

Segment Analysis

The global bowel management systems is segmented based on product type, application, patient type, end-user and region.

The colostomy bags from the product type segment accounted for approximately 41.2% of the market share

The colostomy bags from the product type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A colostomy bag is a plastic bag that collects faecal matter, also called stool or poop, from the digestive tract through an opening in the abdominal wall called a stoma. Doctors attach a bag to the stoma following a colostomy operation.

A colostomy bag, also called a stoma bag or ostomy bag, is a small, waterproof pouch used to collect waste from the body. During a surgical procedure known as a colostomy, an opening called a stoma or ostomy is formed between the large intestine (colon) and the abdominal wall. This allows waste products to be excreted through the opening in the abdominal wall rather than via the colon through the rectum and anus.

For instance, in December 2021, Coloplast launched a clinical trial to test the effect of its ostomy product, Heylo, a product that uses sensors to warn patients with colostomy bags about leakage and advise them about how to prevent it. Thus, the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors such as the rising prevalence of colorectal cancer and the growing geriatric population. Additionally, increased patient awareness, rising adoption rates of intestinal management systems, increasing investments in product development, excellently established healthcare infrastructure, and strong acceptance of developed products are some of the key factors ensuring the region's dominance.

For instance, in May 2023 Advanced Medical Balloons GmbH (formerly Creative Balloons GmbH), a specialist in medical technology from Waghaeusel near Heidelberg, stated that the company is expanding its intensive care business to the United States.

This is based on the approval which has recently been granted by the U.S. Food and Drug Administration (FDA) for their innovative catheter system hygh-tec. The novel faecal management system hygh-tec provides maximum seal and prevention of faecal leakage in patients receiving intensive care.

Moreover, in July 2021 Trio Healthcare secured a second round of funding from US specialist finance company, SWK Holdings Corporation. The funding, approximately $10m in total, will support Trio's R&D and manufacturing as it scales up operations to support a large-scale global roll-out of Trio's world-first stoma bag, GeniiTM

COVID-19 Impact Analysis

COVID-19 had a substantial impact on bowel management systems. Amidst the outbreak of the COVID-19 pandemic, there has been a rise in other health complications that rose with COVID-19 infections. According to a report by the surveillance epidemiology of coronavirus Under Research Exclusion (SECURE-IBD) database published in January 2022 mentioned that adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with inflammatory bowel disease (IBD).

Competitive Landscape

The major global players in the bowel management systems market include: Becton, Dickinson and Company, Coloplast Pty Ltd., ConvaTec Group plc., B Braun SE., Consure Medical Pvt. Ltd., GBUK Group Ltd., Wellandmedical, Wellspect, ProSys International Ltd Qufora and among others.

Key Developments

  • In April 2022, Microbiotica received project funding from the crohn's and colitis foundation as a part of their inflammatory bowel disease ventures program for the development of therapies to treat inflammatory bowel disease.
  • In November 2021, Medtronic plc, a global leader in healthcare technology, stated that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures. The PillCam SB3 @HOME program combines Medtronic's PillCam technology with Amazon logistics, a combination intended to ensure both timely and accurate results for patients from the comfort of their homes.
  • In May 2021, Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, stated European CE Mark approval of its second-generation Axonics r-SNM implantable neurostimulator (INS) and wireless patient remote control with SmartMRI technology.

Why Purchase the Report?

  • To visualize the global bowel management systems market segmentation-based product type, application, patient type, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analysing trends and co-development
  • Excel data sheet with numerous data points of bowel management systems market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global bowel management systems market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Patient Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in the technology advancements
      • 4.1.1.2. Rise in the product launches by key players
    • 4.1.2. Restraints
      • 4.1.2.1. Long-term patient rehabilitation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Colostomy Bags*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Irrigation Systems
  • 7.4. Nerve Modulation Devices
  • 7.5. Others

8. By Patient Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 8.1.2. Market Attractiveness Index, By Patient Type
  • 8.2. Adults*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Pediatric

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Spinal Cord Injury*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Neurological Disorders
  • 9.4. Multiple Sclerosis
  • 9.5. Stroke

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Ambulatory Surgical Centers (ASCs)
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Becton, Dickinson and Company
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Coloplast Pty Ltd.
  • 13.3. ConvaTec Group plc.
  • 13.4. B Braun SE.
  • 13.5. Consure Medical Pvt. Ltd.
  • 13.6. GBUK Group Ltd.
  • 13.7. Wellandmedical
  • 13.8. Wellspect
  • 13.9. ProSys International Ltd
  • 13.10. Qufora

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us